Trial Profile
An Open-label Pilot Study to Determine the Safety and Efficacy of Fixed-dose Glecaprevir and Pibrentasvir Treatment in Hepatitis C Uninfected Recipients of Renal Transplants From Hepatitis C Infected Deceased Donors
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Oct 2021
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms REHANNA
- 10 Sep 2020 Status changed from active, no longer recruiting to completed.
- 21 May 2020 Planned End Date changed from 1 May 2020 to 1 Sep 2020.
- 05 Sep 2019 Planned End Date changed from 1 Aug 2020 to 1 May 2020.